← All companies
About this company
SYDRA AG is a Swiss longevity biotech developing an AI-assisted, phenotype-first drug discovery platform for age-associated diseases. We generate or prioritize small molecules with AI, validate lifespan and healthspan effects in vivo (*C. elegans* ? elderly mice), then identify targets and mechanisms to build de-risked preclinical drug candidates. Our primary customers are pharma and biotech companies seeking partner-ready assets for licensing or co-development. SYDRA has validated 5 geroprotectors in worms, with 2 leads improving lifespan/healthspan in elderly mice. The market opportunity is the >$1T global medicines market driven by age-related diseases.